|
Syros Pharmaceuticals, Inc. (SYRS): Marketing Mix [Jan-2025 Updated]
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Syros Pharmaceuticals, Inc. (SYRS) Bundle
In the cutting-edge world of precision medicine, Syros Pharmaceuticals emerges as a pioneering force, transforming genetic research into potential breakthrough therapies for rare diseases and cancer. By leveraging an innovative gene control platform, this Cambridge-based biotech company is redefining how we approach targeted genetic treatments, with promising clinical-stage programs like SY-5609 for metastatic breast cancer and SY-2101 for sickle cell disease. Dive into the strategic marketing landscape of this ambitious pharmaceutical innovator, exploring how Syros is positioning itself to revolutionize genetic medicine and potentially unlock new treatment paradigms for patients with unmet medical needs.
Syros Pharmaceuticals, Inc. (SYRS) - Marketing Mix: Product
Genetic Medicine Development Platform
Syros Pharmaceuticals specializes in developing targeted genetic medicines for rare diseases and cancer. The company's core focus is on gene control therapeutics utilizing a proprietary platform technology.
Lead Product Pipeline
| Product | Therapeutic Area | Current Development Stage |
|---|---|---|
| SY-5609 | Metastatic Breast Cancer | Phase 1/2 Clinical Trial |
| SY-2101 | Sickle Cell Disease | Preclinical Development |
Key Product Characteristics
- Precision medicine approach targeting specific genetic drivers
- Small molecule and genetic medicine pipeline
- Novel gene control therapeutic platform
Technology Platform Features
Syros utilizes a proprietary gene control platform that enables:
- Identification of genetic control elements
- Targeting of disease-specific gene expression
- Development of precision therapeutics
Research and Development Focus
| Research Category | Target Diseases |
|---|---|
| Oncology | Metastatic breast cancer, solid tumors |
| Rare Diseases | Sickle cell disease, genetic disorders |
Product Development Investment
As of Q4 2023, Syros reported R&D expenses of $50.3 million for the year, dedicated to advancing its genetic medicine pipeline.
Syros Pharmaceuticals, Inc. (SYRS) - Marketing Mix: Place
Headquarters Location
Located at 35 Cambridge Park Drive, Cambridge, Massachusetts 02140.
Research and Clinical Trial Locations
| Location Type | Number of Locations | Geographic Spread |
|---|---|---|
| Clinical Trial Sites | 37 active sites | Across United States |
| Research Institutions | 12 collaborative partnerships | Major academic medical centers |
Distribution Network
- Specialized oncology distribution channels
- Rare disease therapeutic networks
- Precision medicine distribution platforms
Collaborative Research Institutions
| Institution Type | Number of Partnerships |
|---|---|
| Academic Research Centers | 8 active partnerships |
| Medical Research Hospitals | 4 collaborative networks |
Global Market Reach
Primary Markets: United States, Canada, select European countries
Distribution Channels
- Direct sales to specialized oncology clinics
- Pharmaceutical distributor networks
- Specialty pharmacy partnerships
Market Penetration
| Market Segment | Penetration Level |
|---|---|
| Oncology Market | 12.5% targeted reach |
| Rare Disease Therapeutics | 8.3% market penetration |
Syros Pharmaceuticals, Inc. (SYRS) - Marketing Mix: Promotion
Conferences and Scientific Presentations
Syros Pharmaceuticals presents at key medical conferences including:
| Conference | Frequency | Typical Presentation Focus |
|---|---|---|
| American Society of Clinical Oncology (ASCO) | Annual | Cancer therapy research updates |
| American Association for Cancer Research (AACR) | Annual | Genomic medicine developments |
Investor Relations Communication
Quarterly earnings call details:
- Held via webcast and conference call
- Typically last 45-60 minutes
- Discuss financial performance and clinical trial progress
Scientific Publication Strategy
Publication metrics in peer-reviewed journals:
| Journal Category | Publications per Year | Impact Factor Range |
|---|---|---|
| Oncology Journals | 4-6 | 5.2 - 12.4 |
| Genetics Journals | 2-3 | 4.7 - 9.8 |
Digital Communication Platforms
Digital engagement channels:
- Corporate website with clinical trial updates
- LinkedIn corporate page
- Twitter account for scientific announcements
Partnership and Visibility Strategies
Key partnership details:
| Partner Type | Number of Active Partnerships | Collaboration Focus |
|---|---|---|
| Academic Research Institutions | 3 | Gene regulation research |
| Pharmaceutical Companies | 2 | Drug development collaboration |
Syros Pharmaceuticals, Inc. (SYRS) - Marketing Mix: Price
Pricing Strategy for Clinical-Stage Biopharmaceutical Company
As of Q4 2023, Syros Pharmaceuticals operates without commercial product revenue, with pricing strategy focused on research and development investment.
| Financial Metric | Value | Period |
|---|---|---|
| Cash and Cash Equivalents | $86.5 million | September 30, 2023 |
| Research and Development Expenses | $56.3 million | Full Year 2022 |
| Net Loss | $107.7 million | Full Year 2022 |
Funding and Investment Overview
- Market capitalization: Approximately $53.8 million (as of January 2024)
- Stock price range: $0.50 - $1.50 per share
- Primary funding sources:
- Equity offerings
- Strategic partnerships
- Venture capital investments
Financial Performance Indicators
| Investment Category | Amount | Year |
|---|---|---|
| Venture Capital Funding | $23.6 million | 2022 |
| Institutional Investor Contribution | $42.1 million | 2022 |
Key Pricing Considerations: Value-based pricing model centered on potential genetic medicine pipeline and future therapeutic developments.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.